Better days and better nights start with Omnipod® 5

Spend less time managing diabetes while spending more time in range, so you can focus on what matters most.

More time for life. More time in range.

Omnipod® 5 continuously receives glucose readings from a compatible CGM and automatically increases, decreases or pauses insulin delivery based on predicted glucose levels.

The result is a system designed to help keep glucose levels in range^1,2while reducing the day-to-day effort of diabetes management.

Controller, Pod, and Dexcom G7, and FSL2 sensors

Omnipod 5 is compatible with Dexcom G7 CGM System and FreeStyle Libre 2 Plus sensor.

Pod shown without the necessary adhesive. Screen for illustrative purposes only.
*Sensor sold separately and requires a separate prescription.

Why people switch to Omnipod® 5

From multiple daily injections (MDI)

Spend an average of 5.4 more hours per day in range, with no increase in time below range³
Replace multiple daily injections with one Pod for up to 3 days (72 hours)
Automated insulin adjustments every 5 minutes

Podder Skye, jumping in the swimming pool

The Pod has a waterproof IP28 rating for up to 7.6 metres for 60 minutes. The PDM/Controller is not waterproof.

From a traditional tubed insulin pump

Small Pod worn directly on the body
Completely tubeless, with no tubing to disconnect or catch
91% of users said they would not go back to a tubed pump⁴

More than just a tubeless insulin pump

Omnipod 5 automatically adjusts insulin delivery to help keep glucose levels steadier, day and night. Approved for people with T1D ages 2-and-up.

Improves time in range

an average of 5.4 hours per day
with no increase in time below range⁵

Easy to Use

90% of Podders say
Omnipod 5 is easy to use⁶

Peace of mind

92% of Podders say
Omnipod 5 gives them peace of mind⁷

Less calculating at mealtimes

Save frequently eaten foods, meals, or snacks with preset carb amounts, then let the SmartBolus Calculator do the math for you. Perfect for:

repeat meals
kids' lunches
favourite snacks
busy schedules.

woman at a restaurant smiling while looking at a phone

Designed to keep up with life

When enabled, the Activity feature reduces insulin delivery when glucose has the potential to go low. Ideal for:

Exercise
Sleepovers
Sick days
Any time you want reduced insulin delivery

Omnipod is available on the NDSS

Omnipod® 5 is partially subsidised through the NDSS for eligible people with type 1 diabetes, helping to reduce the ongoing cost of Omnipod 5 Pods.

A patient receives Pods from a pharmacist at the pharmacy.

Hear real Podder stories

You can almost forget about having type one wearing this pump... it's given me the first idea of what it's like to live with a working pancreas.

Richard
Podder® since 2024

Omnipod 5 has allowed us to give Priya the freedom that all kids deserve, whilst not compromising her safety or worrying about disconnecting her from her insulin delivery.

Kimmie – Mother of Priya
Podder® since 2023

Omnipod 5 reduces the burden of diabetes, it increases your quality of life and I couldn’t have even imagined something like this when I was first diagnosed.

Lydia P.
Podder® since 2014

Try it before committing

Order a free Pod Experience Kit* to get a feel for Omnipod in your daily routine. No needles, no commitment.

If you have Type 2 Diabetes please speak with your healthcare professional before you request a call as you might not be considered suitable to use Omnipod®

Indicates required field

First Name

Last Name

Type of Diabetes

Current Treatment Type

Current Sensor

Phone Number

Postal Code

Email Address

How did you hear about Omnipod®?

Preferred Contact Time

Selection 1 Morning

Selection 1 Afternoon

Selection 1 Anytime

Selection 1 I certify I am 18 years of age or older. If you are under 18, please ask your parent or guardian to complete on your behalf.

Selection 1 In order to send you Insulet updates and marketing messages and texts, to call you for marketing purposes, and to tailor our marketing content via any Insulet marketing channels (i.e. email marketing or third-party advertising platforms), we need to collect, use and disclose your personal information, including health information. We may transfer your personal information outside of Australia, to countries which may not protect your personal information in line with the Privacy Act 1988. If you tick the box you provide your express consent to this processing of your personal and health information for these purposes. Please see our Privacy Policy for more information and for information on how you can withdraw your consent.

1. Brown S. et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Average time with low blood glucose in adults/adolescents and children, standard therapy vs 3-month Omnipod 5: 2.9% vs. 1.3%; 2.2% vs. 1.8%. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 in adults/adolescents and children = 64.7% vs. 73.9%; 52.5% vs. 68.0%.

2. Sherr JL, et al. Diabetes Care (2022). Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in very young children, standard therapy vs 3-month Omnipod 5: 39.4% vs. 29.5%. Average time with low blood glucose in very young children, standard therapy vs 3-month Omnipod 5: 3.43% vs. 2.46%. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 = 57.2% vs. 68.1%.

3. Wilmot E, et al. Lancet (2026); A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) [51% HbA1c≥ 8% (64 mmol/mol)] with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. Time in range (70-180 mg/dL or 3.9-10mmol/L) with OP5 improved by 22% (43% MDI vs. 65% OP5, p<0.001). Time below range (<70 mg/dL or <3.9mmol/L) with OP5 was non-inferior to MDI (2.27% MDI vs. 2.56%, p=0.2).

4. 2025 Customer Survey of U.S. adults with Type 1 diabetes using Omnipod 5, (n=1,230), 91% agreed would not go back to tubes. Data on file. RF-082025-00063.

5. Wilmot E, et al. Lancet (2026); A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) [51% HbA1c≥ 8% (64 mmol/mol)] with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. Time in range (70-180 mg/dL or 3.9-10mmol/L) with OP5 improved by 22% (43% MDI vs. 65% OP5, p<0.001). Time below range (<70 mg/dL or <3.9mmol/L) with OP5 was non-inferior to MDI (2.27% MDI vs. 2.56%, p=0.2). Study funded by Insulet.

6. Insulet Data on File. 2024. A 13-week randomised controlled trial conducted among 194 adults (age 18-70 years) with type 1 diabetes in France and the U.S., comparing the safety and effectiveness of the Omnipod 5 Automated Insulin Delivery (AID) System versus conventional non-AID pump therapy and CGM (control). At 13-weeks of Omnipod 5 use 130 participants were asked via a System Usability Survey (SUS) if the system was easy to use. 71.5% of participants strongly agreed and 19.2% agreed. RF-112024-00029. Study funded by Insulet

7. 2025 Customer Survey of U.S. adults with Type 1 diabetes (n=1230), 92% agreed Omnipod 5 gives them peace of mind. Survey funded by Insulet.